WAYNE, Pa., March 9, 2021 (GLOBE NEWSWIRE) – Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift® System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH).
In the United States alone, more than 42 million men are affected by BPH and approximately 12 million men are under a doctor’s care for the condition.1 This common, non-cancerous enlargement of the prostate occurs as men age and can interrupt sleep, cause urinary problems, and decrease quality of life.2
“The UroLift System is a standard of care in my practice, and I confidently recommend it to appropriate patients who face the challenge of an enlarging prostate,” said Wayne Kuang, M.D.a “Many men are looking for alternatives to medications and major surgeries that have unwanted side effects and risks. The UroLift System may enable men to experience rapid symptom relief, recover from the procedure quickly, and return to their normal routines with minimal downtime.3,4 This minimally invasive procedure can achieve consistent results in a broad range of BPH patients with various anatomies and a wide range of sizes.”
“Celebrating 250,000 patients treated with the UroLift System is an exciting milestone. We thank the physicians in our community who recommend the UroLift System to their patients,” said Tyler Binney, President of the Teleflex Interventional Urology business unit. “Recent clinical data show the UroLift System provides a superior patient experience with better sexual function, lower catheterization rates, less interference with daily activities, and higher patient satisfaction in the early recovery period.b,5 Patients treated with the UroLift System may also achieve better outcomes in sexual function and satisfaction than men who receive medical therapyc,8 These positive UroLift System outcomes align with our goal at Teleflex to improve the health and quality of patients’ lives.”
About the UroLift® System
The UroLift® System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older. The UroLift permanent implants, delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction or removing prostate tissue. The UroLift System is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.d,3,6,7 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.3 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. More than 250,000 men have been treated with the UroLift System in select markets worldwide.e Learn more at www.UroLift.com.
About Teleflex Interventional Urology
The Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive, and clinically effective devices that address unmet needs in the field of urology. Our focus is on improving the standard of care for patients with BPH using the UroLift® System, a minimally invasive, permanent implant system that treats symptoms while preserving sexual function.d,3,6,7 Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose-driven innovation—a relentless pursuit of identifying unmet clinical needs—to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine, and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck®—trusted brands united by a common sense of purpose.
# # #
For Teleflex Incorporated:
Jake Elguicze, 610.948.2836
Treasurer and Vice President, Investor Relations
Nicole Osmer, 650.454.0504
a Dr. Wayne Kuang is a paid consultant of NeoTract | Teleflex Interventional Urology
b Nonrandomized controlled study comparing the early patient experience following treatment with the UroLift System and Rezum™ steam injection.
c Non-head-to-head comparative study examining erectile and ejaculatory function and sexual satisfaction following treatment with the UroLift System or once-daily medical therapy from the MTOPS trial.
d No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
e Management estimate based on product sales and average units per procedure.
1. NeoTract US Market Model estimates for 2020 based on IQVIA™ data; data on file.
2. Speakman, BJUI 2014
3. Roehrborn, J Urology 2013
4. Shore, Can J Urol 2014
5. Tutrone, Can J Urol 2020
6. AUA BPH Guidelines 2003, 2020
7. McVary, J Sex Med 2016
8. Roehrborn and Rukstalis. Eur Urol Focus 2020
MAC01880-01 Rev A